论文部分内容阅读
许多研究表明,何杰金氏病患者接受烷化剂治疗后白血病的危险增加,为评价不同治疗对何杰金氏病患者发生白血病危险的作用,由加拿大、丹麦、芬兰、挪威、英国、南斯拉夫、荷兰、法国、意大利九国12个癌症登记处及6个肿瘤医院组成的癌症协作组对1960年1月以后诊断的29552例何杰金氏病患者进行病例-对照研究.根据上述癌症登记处及肿瘤医院的记录,共有163例何杰金氏病患者发生白血病,这些患者白血病的诊断至少在何杰金氏病诊断后一年,每个患者以三个相匹配的未发生白血病的何杰金氏病病例作为对照,有关指标经统计学处理.结果发现,急性白血病及非淋巴细胞性白血病占全部白血病病例的91%.与单独放疗比较,单独化疗白血病的相对危险性为9.0(4.1-20、95%可
Numerous studies have shown that the risk of leukemia increases in patients with Hodgkin’s disease after being treated with alkylating agents. In order to assess the risk of developing leukemia in patients with Hodgkin’s disease with different therapies, Canada, Denmark, Finland, Norway, the United Kingdom, Yugoslavia , The Cancer Collaborative Group comprising 12 cancer registries in the Netherlands, France, Italy, nine countries and six oncology hospitals conducted a case-control study of 29,552 Hodgkin’s patients diagnosed after January 1960. Based on the above cancer registry And Tumor Hospital, a total of 163 cases of Hodgkin’s disease in patients with leukemia, the diagnosis of leukemia in these patients at least one year after the diagnosis of Hodgkin’s disease, each patient with three matched He Jie did not occur leukemia According to the statistical analysis of the indicators, the acute leukemia and non-lymphocytic leukemia accounted for 91% of all cases of leukemia.Compared with radiotherapy alone, the relative risk of leukemia chemotherapy alone was 9.0 (4.1- 20,95% can be